D.A. Davidson & CO. Grows Stock Position in DexCom, Inc. (NASDAQ:DXCM)

D.A. Davidson & CO. boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 22.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,578 shares of the medical device company’s stock after acquiring an additional 5,969 shares during the quarter. D.A. Davidson & CO.’s holdings in DexCom were worth $2,184,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in DexCom during the second quarter worth $25,000. Sachetta LLC lifted its stake in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares in the last quarter. DT Investment Partners LLC boosted its holdings in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares during the last quarter. Riverview Trust Co grew its position in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares in the last quarter. Finally, ORG Partners LLC increased its holdings in shares of DexCom by 1,992.0% in the second quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock valued at $59,000 after purchasing an additional 498 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $77.99 on Friday. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock has a market capitalization of $30.46 billion, a PE ratio of 46.70, a PEG ratio of 2.39 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a 50-day simple moving average of $71.39 and a 200-day simple moving average of $88.11.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,431 shares of company stock valued at $399,319. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of a number of recent research reports. Robert W. Baird boosted their price objective on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Raymond James dropped their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Wells Fargo & Company increased their price target on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Finally, Oppenheimer lowered their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.